Care of Patients with Non-small-cell Lung Cancer Stage III – the Central European Real-world Experience

  • Milada Zemanova 1st Faculty of Medicine of Charles University, Prague, Czech Republic
  • Robert Pirker Department of Medicine I, Medical University of Vienna, Vienna, Austria
  • Luboš Petruželka 1st Faculty of Medicine of Charles University, Prague, Czech Republic
  • Zuzana Zbožínková Institute of Biostatistic and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
  • Dragana Jovanovic Clinic for pulmonology, Clinical Centre of Serbia, Belgrade, Serbia
  • Mirjana Rajer Institute of Oncology, Ljubljana, Slovenia
  • Krisztina Bogos National Koranyi Institute of TB and Pulmonology, Budapest, Hungary
  • Gunta Purkalne Pauls Stradins Clinical University Hospital, Riga, Latvia
  • Vesna Ceriman Krstic Clinic for pulmonology, Clinical Centre of Serbia, Belgrade, Serbia
  • Subhash Chaudhary Comprehensive Oncology Center, Nový Jičín, Czech Republic
  • Igor Richter Comprehensive Oncology Center, Liberec, Czech Republic
  • Jiří Kufa Clinic for pneumology & tuberculosis, Faculty of Medicine, Palacký University, Olomouc, Czech Republic
  • Lenka Jakubíková Department of Respiratory Diseases and Tuberculosis, Faculty of Medicine, Masaryk University and University Hospital, Brno, Czech Republic
  • Marius Zemaitis Department of Pulmonology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
  • Markéta Černovská Thomayer Hospital, Prague, Czech Republic
  • Leona Koubková Clinic of Pulmonology, University Hospital Motol, Prague, Czech Republic
  • Zdeňka Vilasová Comprehensive Cancer Center and Multiscan, Pardubice, Czech Republic
  • Karin Dieckmann Medical University of Vienna, Department of Radiotherapy, Vienna, Austria
  • Attila Farkas Department of Thoracic Surgery, National Institute of Oncology, Budapest, Hungary
  • Jelena Spasic Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
  • Kateřina Fröhlich Institute of Biostatistic and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
  • Andreas Tiefenbacher Department of Medicine I, Medical University of Vienna, Vienna, Austria
  • Virág Hollósi National Koranyi Institute of TB and Pulmonology, Budapest, Hungary
  • Juraj Kultan Clinic for pneumology & tuberculosis, Faculty of Medicine, Palacký University, Olomouc, Czech Republic
  • Iveta Kolářová Comprehensive Cancer Center and Multiscan, Pardubice, Czech Republic
  • Jiří Votruba 1st Faculty of Medicine of Charles University, Prague, Czech Republic

Abstract

Introduction

Management of non-small-cell lung cancer (NSCLC) is affected by regional specificities. The present study aimed at determining diagnostic and therapeutic procedures including outcome of patients with NSCLC stage III in the real-world setting in Central European countries to define areas for improvements.

Patients and Methods.

This multicentre, prospective and non-interventional study collected data of patients with NSCLC stage III in a web-based registry and analysed them centrally.

Results.

Patients (n=583) with the following characteristics were entered: 32% females, 7% never-smokers; ECOG PS 0, 1, 2 and 3 in 25%, 58%, 12% and 5%, respectively; 21% prior weight loss; 53% squamous carcinoma, 38% adenocarcinoma; 10% EGFR mutations. Staging procedures included chest X-ray (97% of patients), chest CT (96%), PET-CT (27%), brain imaging (20%), bronchoscopy (89%), EBUS (13%) and CT-guided biopsy (9%). Stages IIIA/IIIB were diagnosed in 55%/45% of patients, respectively. N2/N3 nodes were diagnosed in 60%/23% and pathologically confirmed in 29% of patients. The majority of patients (56%) were treated by combined modalities. Surgery plus chemotherapy was administered to 20%, definitive chemoradiotherapy to 34% and chemotherapy only to 26% patients. Median survival and progression-free survival times were 17 and 11 months, respectively. Stage IIIA, female gender, no weight loss, pathological mediastinal lymph node verification, surgery and combined modality therapy were associated with longer survival.

Conclusion.

The real-world study demonstrated a broad heterogeneity in the management of stage III NSCLC in Central European countries and suggested to increase the rates of PET-CT imaging, brain imaging and invasive mediastinal staging.

Published
2020-05-31
How to Cite
Zemanova, M., Pirker, R., Petruželka, L., Zbožínková, Z., Jovanovic, D., Rajer, M., Bogos, K., Purkalne, G., Ceriman Krstic, V., Chaudhary, S., Richter, I., Kufa, J., Jakubíková, L., Zemaitis, M., Černovská, M., Koubková, L., Vilasová, Z., Dieckmann, K., Farkas, A., Spasic, J., Fröhlich, K., Tiefenbacher, A., Hollósi, V., Kultan, J., Kolářová, I., & Votruba, J. (2020). Care of Patients with Non-small-cell Lung Cancer Stage III – the Central European Real-world Experience . Radiology and Oncology, 54(2), 209-220. Retrieved from https://radioloncol.com/index.php/ro/article/view/3384
Section
Clinical oncology